Kono et al. found that the immune responses induced by three HLA-A24-binding peptides (IGF2BP3, LY6K, TTK) improved the prognosis in patients with advanced esophageal squamous cell carcinoma [99]. Here, IGF2BP3 is linked to esophageal squamous cell carcinoma.